Protein arginine methyltransferases: promising targets for cancer therapy
활용도 Analysis
논문 Analysis
연구자 Analysis
'
Protein arginine methyltransferases: promising targets for cancer therapy' 의 참고문헌
p53-Independent regulation of p21Waf1/Cip1 expression and senescence by PRMT6
beta-Catenin primes organizer gene expression by recruiting a histone H3 arginine 8methyltransferase, Prmt2
Versatility of PRMT5-induced methylation in growth control and development
Unique features of human protein arginine methyltransferase 9(PRMT9)and its substrate RNA splicing factor SF3B2
Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation
The regulation, functions and clinical relevance of arginine methylation
The protein arginine methyltransferase Prmt5 is required for myogenesis because it facilitates ATPdependent chromatin remodeling
The multiple mechanisms that regulate p53 activity and cell fate
The methylosome, a 20S complex containing JBP1 and pICln, produces dimethylarginine-modified Sm proteins
The methylation of the C-terminal region of hnRNPQ(NSAP1)is important for its nuclear localization
The emergence of protein arginine methyltransferases in skeletal muscle and metabolic disease
The dual function of PRMT1 in modulating epithelialmesenchymal transition and cellular senescence in breast cancer cells through regulation of ZEB1
The dual epigenetic role of PRMT5 in acute myeloid leukemia : gene activation and repression via histone arginine methylation
The cell cycle : a review of regulation, deregulation and therapeutic targets in cancer
The arginine methyltransferase PRMT6 regulates cell proliferation and senescence through transcriptional repression of tumor suppressor genes
The arginine methyltransferase PRMT6 regulates DNA methylation and contributes to global DNA hypomethylation in cancer
The arginine methyltransferase PRMT1 regulates IGF-1signaling in breast cancer
The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing
The RGG domain in hnRNP A2 affects subcellular localization
The PRMT5/WDR77 complex regulates alternative splicing through ZNF326 in breast cancer
The PRMT5 arginine methyltransferase : many roles in development, cancer and beyond
The MRE11 GAR motif regulates DNA double-strand break processing and ATR activation
The Kruppel-like zinc finger protein ZNF224 recruits the arginine methyltransferase PRMT5 on the transcriptional repressor complex of the aldolase A gene
The GAR motif of 53BP1 is arginine methylated by PRMT1 and is necessary for 53BP1 DNA binding activity
The C-terminal RGG domain of human Lsm4 promotes processing body formation stimulated by arginine dimethylation
The C-terminal RG dipeptide repeats of the spliceosomal Sm proteins D1 and D3 contain symmetrical dimethylarginines, which form a major B-cell epitope for anti-Sm autoantibodies
The BTG2-PRMT1 module limits pre-B cell expansion by regulating the CDK4-Cyclin-D3 complex
Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia
Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth
Target-based approach to inhibitors of histone arginine methyltransferases
TP-064, a potent and selective small molecule inhibitor of PRMT4 for multiple myeloma
Symmetrical dimethylation of arginine residues in spliceosomal Sm protein B/B’and the Sm-like protein LSm4, and their interaction with the SMN protein
Symmetrical dimethylarginine methylation is required for the localization of SMN in Cajal bodies and pre-mRNA splicing
Structure and property guided design in the identification of PRMT5 tool compound EPZ015666
Structural biology and chemistry of protein arginine methyltransferases
Structural basis of arginine asymmetrical dimethylation by PRMT6
Spliceosome Sm proteins D1, D3, and B/B’ are asymmetrically dimethylated at arginine residues in the nucleus
Specific protein methylation defects and gene expression perturbations in coactivator-associated arginine methyltransferase 1-deficient mice
Small molecule regulators of protein arginine methyltransferases
Severe hypomyelination and developmental defects are caused in mice lacking protein arginine methyltransferase 1(PRMT1)in the central nervous system
SMN, the product of the spinal muscular atrophy gene, binds preferentially to dimethylarginine-containing protein targets
SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth
S-adenosylmethionine: protein-arginine methyltransferase. Purification and mechanism of the enzyme
Ribosomal protein rpS2 is hypomethylated in PRMT3-deficient mice
Regulation of coactivator complex assembly and function by protein arginine methylation and demethylimination
Regulation of chromatin by histone modifications
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
Regulated recruitment of tumor suppressor BRCA1 to the p21 gene by coactivator methylation
Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy
Protein arginine methyltransferases and cancer
Protein arginine methyltransferases : insights into the enzyme structure and mechanism at the atomic level
Protein arginine methyltransferase 7 regulates cellular response to DNA damage by methylating promoter histones H2A and H4 of the polymerase delta catalytic subunit gene, POLD1
Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression
Protein arginine methyltransferase 5promotes bladder cancer growth through inhibiting NF-kB dependent apoptosis
Protein arginine methyltransferase 5-mediated epigenetic silencing of IRX1 contributes to tumorigenicity and metastasis of gastric cancer
Protein arginine methyltransferase 5(PRMT5)promotes survival of lymphoma cells via activation of WNT/beta-catenin and AKT/GSK3beta proliferative signaling
Protein arginine methyltransferase 5(PRMT5)inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2(PRC2)silencing
Protein arginine methyltransferase 5(PRMT5)dysregulation in cancer
Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells
Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma
Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF
Protein arginine methyltransferase 5 promotes pIClndependent androgen receptor transcription in castration-resistant prostate cancer
Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling
Protein arginine methyltransferase 5 mediates enolase-1cell surface trafficking in human lung adenocarcinoma cells
Protein arginine methyltransferase 5 is implicated in the aggressiveness of human hepatocellular carcinoma and controls the invasive activity of cancer cells
Protein arginine methyltransferase 5 is essential for growth of lung cancer cells
Protein arginine methyltransferase 5 is associated with malignant phenotype and peritoneal metastasis in gastric cancer
Protein arginine methyltransferase 5 is a potential oncoprotein that upregulates G1 cyclins/cyclin-dependent kinases and the phosphoinositide 3-kinase/AKT signaling cascade
Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth
Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4
Protein arginine methyltransferase 3-induced metabolic reprogramming is a vulnerable target of pancreatic cancer
Protein arginine methyltransferase 1 promoted the growth and migration of cancer cells in esophageal squamous cell carcinoma
Protein arginine methylation in mammals : who, what, and why
Proliferative role of TRAF4 in breast cancer by upregulating PRMT5 nuclear expression
Prmt7 promotes myoblast differentiation via methylation of p38MAPK on arginine residue 70
Prmt5 is essential for early mouse development and acts in the cytoplasm to maintain ES cell pluripotency
Pharmacological inhibition of PRMT7 links arginine monomethylation to the cellular stress response
PROTACs : great opportunities for academia and industry
PROTAC technology : opportunities and challenges
PRMTs and arginine methylation: cancer’s best-kept secret?
PRMT9 promotes hepatocellular carcinoma invasion and metastasis via activating PI3K/Akt/GSK-3beta/Snail signaling
PRMT9 is a type II methyltransferase that methylates the splicing factor SAP145
PRMT7 promotes the growth of renal cell carcinoma through modulating the beta-catenin/C-MYC axis
PRMT7 methylates eukaryotic translation initiation factor 2alpha and regulates its role in stress granule formation
PRMT7 methylates and suppresses GLI2 binding to SUFU thereby promoting its activation
PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer
PRMT7 contributes to the metastasis phenotype in human non-small-cell lung cancer cells possibly through the interaction with HSPA5and EEF2
PRMT7 as a unique member of the protein arginine methyltransferase family : a review
PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation
PRMT6-mediated H3R2me2a guides Aurora B to chromosome arms for proper chromosome segregation
PRMT6 serves an oncogenic role in lung adenocarcinoma via regulating p18
PRMT6 regulates RAS/RAF binding and MEK/ERK-mediated cancer stemness activities in hepatocellular carcinoma through CRAF methylation
PRMT6 promotes lung tumor progression via the alternate activation of tumor-associated macrophages
PRMT6 promotes endometrial cancer via AKT/mTOR signaling and indicates poor prognosis
PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing
PRMT5-mediated methylation of YBX1 regulates NFkappaB activity in colorectal cancer
PRMT5-mediated methylation of NF-kappaB p65 at Arg174 is required for endothelial CXCL11 gene induction in response to TNF-alpha and IFN-gamma costimulation
PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression
PRMT5-dependent methylation of the TIP60 coactivator RUVBL1 is a key regulator of homologous recombination
PRMT5 regulates IRES-dependent translation via methylation of hnRNP A1
PRMT5 regulates DNA repair by controlling the alternative splicing of histone-modifying enzymes
PRMT5 promotes epithelial-mesenchymal transition via EGFRbeta-catenin axis in pancreatic cancer cells
PRMT5 promotes cell proliferation by inhibiting BTG2expression via the ERK signaling pathway in hepatocellular carcinoma
PRMT5 promotes DNA repair through methylation of 53BP1 and is regulated by Src-mediated phosphorylation
PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia
PRMT5 is upregulated by B-cell receptor signaling and forms a positive-feedback loop with PI3K/AKT in lymphoma cells
PRMT5 is required for cell-cycle progression and p53 tumor suppressor function
PRMT5 is a critical regulator of breast cancer stem cell function via histone methylation and FOXP1 expression
PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis
PRMT5 dimethylates R30 of the p65 subunit to activate NFkappaB
PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer
PRMT5 competitively binds to CDK4 to promote G1-S transition upon glucose induction in hepatocellular carcinoma
PRMT5 associates with the FOXP3 homomer and when disabled enhances targeted p185(erbB2/neu)tumor immunotherapy
PRMT4 blocks myeloid differentiation by assembling a methylRUNX1-dependent repressor complex
PRMT3 inhibits ubiquitination of ribosomal protein S2 and together forms an active enzyme complex
PRMT2 links histone H3R8 asymmetric dimethylation to oncogenic activation and tumorigenesis of glioblastoma
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response
PRMT1 regulates tumor growth and metastasis of human melanoma via targeting ALCAM
PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP
PRMT1 loss sensitizes cells to PRMT5 inhibition
PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells
PRMT1 is critical to FEN1 expression and drug resistance in lung cancer cells
PRMT1 is a novel regulator of epithelial-mesenchymaltransition in non-small cell lung cancer
PRMT1 expression is elevated in head and neck cancer and inhibition of protein arginine methylation by adenosine dialdehyde or PRMT1 knockdown downregulates proliferation and migration of oral cancer cells
PRMT1 activates myogenin transcription via MyoD arginine methylation at R121
PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis
PABP1 identified as an arginine methyltransferase substrate using high-density protein arrays
Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer
Oncogenic functions of Gli1 in pancreatic adenocarcinoma are supported by its PRMT1-mediated methylation
Nuclear loss of protein arginine N-methyltransferase 2 in breast carcinoma is associated with tumor grade and overexpression of cyclin D1 protein
Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC
Negative regulation of transcription by the type II arginine methyltransferase PRMT5
Myosin phosphatase and RhoA-activated kinase modulate arginine methylation by the regulation of protein arginine methyltransferase 5 in hepatocellular carcinoma cells
Minireview : protein arginine methylation of nonhistone proteins in transcriptional regulation
Methylation specifies distinct estrogen-induced binding site repertoires of CBP to chromatin
Methylation of the tumor suppressor protein, BRCA1, influences its transcriptional cofactor function
Methylation of ribosomal protein S10 by protein-arginine methyltransferase 5 regulates ribosome biogenesis
Methylation of histone H4 by arginine methyltransferase PRMT1 is essential in vivo for many subsequent histone modifications
Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1
Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor
Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive
Methylation of histone H3 by coactivator-associated arginine methyltransferase 1
Methylation of arginine by PRMT1 regulates Nrf2 transcriptional activity during the antioxidative response
Methylation of Sm proteins by a complex containing PRMT5and the putative U snRNP assembly factor pICln
Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity
Methylation of MRE11regulates its nuclear compartmentalization
Methylation of HSP70 orchestrates its binding to and stabilization of BCL2 mRNA and renders pancreatic cancer cells resistant to therapeutics
Methylation of H2AR29 is a novel repressive PRMT6target
Methylation of FEN1 suppresses nearby phosphorylation and facilitates PCNA binding
Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis
Methylation of DNA polymerase beta by protein arginine methyltransferase 1 regulates its binding to proliferating cell nuclear antigen
Methylation of C/EBPalpha by PRMT1 inhibits its tumorsuppressive function in breast cancer
Mammalian cell-cycle regulation : several Cdks, numerous cyclins and diverse compensatory mechanisms
MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis
MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
MEP50/PRMT5-mediated methylation activates GLI1 in Hedgehog signalling through inhibition of ubiquitination by the ITCH/NUMB complex
MED12 methylation by CARM1 sensitizes human breast cancer cells to chemotherapy drugs
LLY-283, a potent and selective inhibitor of arginine methyltransferase 5, PRMT5, with antitumor activity
KH-type splicing regulatory protein interacts with survival motor neuron protein and is misregulated in spinal muscular atrophy
JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation
Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis
In vivo and in vitro arginine methylation of RNA-binding proteins
Identification of a CARM1 inhibitor with potent in vitro and in vivo activity in preclinical models of multiple myeloma
Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma
Human protein arginine methyltransferase 7(PRMT7)is a type III enzyme forming omega-NGmonomethylated arginine residues
Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes
Hormone-dependent, CARM1-directed, arginine-specific methylation of histone H3 on a steroid-regulated promoter
Histone arginine methylations : their roles in chromatin dynamics and transcriptional regulation
HOXA9 methylation by PRMT5 is essential for endothelial cell expression of leukocyte adhesion molecules
H3R42me2a is a histone modification with positive transcriptional effects
Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma
Exploration of cyanine compounds as selective inhibitors of protein arginine methyltransferases : synthesis and biological evaluation
Epigenetic modifications of histones in cancer
Enzymatic methylation of protein fractions from calf thymus nuclei
Enhanced arginine methylation of programmed cell death 4 protein during nutrient deprivation promotes tumor cell viability
ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor
Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers
Disordered methionine metabolism in MTAP/CDKN2Adeleted cancers leads to dependence on PRMT5
Discovery of first-in-class protein arginine methyltransferase 5(PRMT5)degraders
Discovery of a potent, selective, and cell-active dual inhibitor of protein arginine methyltransferase 4 and protein arginine methyltransferase 6
Discovery of a first-in-class protein arginine methyltransferase 6(PRMT6)covalent inhibitor
Discovery of a dual PRMT5-PRMT7 inhibitor
Diamidine compounds for selective inhibition of protein arginine methyltransferase 1
Determinants of the interaction of the spinal muscular atrophy disease protein SMN with the dimethylarginine-modified box H/ACA small nucleolar ribonucleoprotein GAR1
Crystal structure of the human PRMT5 : MEP50 complex
Crosstalk between CARM1 methylation and CBP acetylation on histone H3
Crosstalk between Arg 1175 methylation and Tyr 1173phosphorylation negatively modulates EGFR-mediated ERK activation
Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing
Cross-talk between Arg methylation and Ser phosphorylation modulates apoptosis signal-regulating kinase 1 activation in endothelial cells
Control of CBP co-activating activity by arginine methylation
Coilin methylation regulates nuclear body formation
Coactivator-associated arginine methyltransferase 1(CARM1)is a positive regulator of the Cyclin E1 gene
Cellular localization of protein arginine methyltransferase-5correlates with grade of lung tumors
Cell cycle regulation by the PRMT6 arginine methyltransferase through repression of cyclin-dependent kinase inhibitors
CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity
CARM1 regulates estrogenstimulated breast cancer growth through up-regulation of E2F1
CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis
CARM1 methylates GAPDH to regulate glucose metabolism and is suppressed in liver cancer
CARM1 mediates modulation of Sox2
CARM1 is essential for myeloid leukemogenesis but dispensable for normal hematopoiesis
CARM1 is an important determinant of ERalphadependent breast cancer cell differentiation and proliferation in breast cancer cells
CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas
CARM1 contributes to skeletal muscle wasting by mediating FoxO3 activity and promoting myofiber autophagy
Aven recognition of RNA G-quadruplexes regulates translation of the mixed lineage leukemia protooncogenes
Asymmetrical methyltransferase PRMT3 regulates human mesenchymal stem cell osteogenesis via miR-3648
Asymmetric dimethylation at histone H3 arginine 2 by PRMT6in gastric cancer progression
Asymmetric arginine dimethylation of heterogeneous nuclear ribonucleoprotein K by protein-arginine methyltransferase 1inhibits its interaction with c-Src
Asymmetric arginine dimethylation of RelA provides a repressive mark to modulate TNFalpha/NF-kappaB response
Aryl pyrazoles as potent inhibitors of arginine methyltransferases : identification of the first PRMT6 tool compound
Arginine methyltransferase CARM1/PRMT4 regulates endochondral ossification
Arginine methylation: the coming of age
Arginine methylation-dependent regulation of ASK1 signaling by PRMT1
Arginine methylation-dependent reader-writer interplay governs growth control by E2F-1
Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer
Arginine methylation regulates the p53 response
Arginine methylation of ubiquitin-associated protein 2-like is required for the accurate distribution of chromosomes
Arginine methylation of the C-terminus RGG motif promotes TOP3B topoisomerase activity and stress granule localization
Arginine methylation of ribosomal protein S3 affects ribosome assembly
Arginine methylation of STAT1 modulates IFNalpha/betainduced transcription
Arginine methylation of SMAD7 by PRMT1 in TGF-betainduced epithelial-mesenchymal transition and epithelial stem-cell generation
Arginine methylation of SHANK2 by PRMT7 promotes human breast cancer metastasis through activating endosomal FAK signalling
Arginine methylation of RNA-binding proteins regulates cell function and differentiation
Arginine methylation of MRE11 by PRMT1 is required for DNA damage checkpoint control
Arginine methylation of MDH1 by CARM1 inhibits glutamine metabolism and suppresses pancreatic cancer
Arginine methylation of FOXO transcription factors inhibits their phosphorylation by Akt
Arginine methylation initiates BMP-induced Smad signaling
Arginine methylation controls growth regulation by E2F-1
Arginine Nmethyltransferase 1 is required for early postimplantation mouse development, but cells deficient in the enzyme are viable
Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss
An allosteric inhibitor of protein arginine methyltransferase 3
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing
A transcriptional switch mediated by cofactor methylation
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
A role for the arginine methylation of Rad9 in checkpoint control and cellular sensitivity to DNA damage
A proteomic analysis of arginine-methylated protein complexes
A potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases
A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3(PRMT3)
A novel SHARPIN-PRMT5-H3R2me1 axis is essential for lung cancer cell invasion
A coactivator role of CARM1 in the dysregulation of betacatenin activity in colorectal cancer cell growth and gene expression
53BP1 oligomerization is independent of its methylation by PRMT1
'
Protein arginine methyltransferases: promising targets for cancer therapy'
의 유사주제(
